icon
0%

Genmab Stocks - News Analyzed: 3,386 - Last Week: 92 - Last Month: 456

↗ Genmab Targets Future Growth Despite Recent Slump; HC Wainwright Reiterates 'Buy' Rating

Genmab Targets Future Growth Despite Recent Slump; HC Wainwright Reiterates 'Buy' Rating
Genmab, a renowned biotech company, has seen a ton of market activity recently. Despite suffering a slump after a significant move, a $1.8 billion acquisition of ProfoundBio, the company is taking assertive measures such as advancing its share buy-back program and expanding share capital plans. Even as shares have hit a four-year low, Genmab remains a well-regarded investment, with a 'Buy' rating reaffirmed by HC Wainwright and a purchase of over 8000 shares by PNC Financial Services Group Inc. While moving towards the future, Genmab has exciting developments in the pipeline, including a focus on ovarian cancer drugs with the acquisition of ProfoundBio and boasting strong Q1 sales of its drug, DARZALEX. Despite short-term downturns, investors have seen a commendable 82% return in the past five years. Nevertheless, due diligence is vital as financial prospects remain attractive, but risks persist with a recent price drop and significant sell-offs by companies such as Wellington Management Group LLP and Franklin Resources Inc.

Genmab Stocks News Analytics from Wed, 02 Oct 2019 07:00:00 GMT to Sat, 22 Jun 2024 19:16:23 GMT - Rating 2 - Innovation -3 - Information 6 - Rumor 4

The email address you have entered is invalid.